[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenetic Biosciences Inc (XBIO)

Xenetic Biosciences Inc (XBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,332
  • Shares Outstanding, K 2,291
  • Annual Sales, $ 2,980 K
  • Annual Income, $ -2,680 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta 2.19
  • Price/Sales 2.31
  • Price/Cash Flow N/A
  • Price/Book 0.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.75 +16.36%
on 05/21/26
3.49 -8.44%
on 06/04/26
+0.16 (+5.12%)
since 05/15/26
3-Month
2.65 +20.75%
on 03/30/26
3.68 -13.04%
on 04/16/26
+0.39 (+13.97%)
since 03/13/26
52-Week
1.90 +68.42%
on 12/16/25
13.93 -77.03%
on 10/08/25
+0.19 (+6.21%)
since 06/13/25

Most Recent Stories

More News
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion

XBIO : 3.20 (unch)
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies

XBIO : 3.20 (unch)
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development

XBIO : 3.20 (unch)
Xenetic Biosciences: Q1 Earnings Snapshot

Xenetic Biosciences: Q1 Earnings Snapshot

XBIO : 3.20 (unch)
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies...

XBIO : 3.20 (unch)
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers

XBIO : 3.20 (unch)
Xenetic Biosciences: Q4 Earnings Snapshot

Xenetic Biosciences: Q4 Earnings Snapshot

XBIO : 3.20 (unch)
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Adjourns 2025 Annual Meeting of Stockholders

XBIO : 3.20 (unch)
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology...

XBIO : 3.20 (unch)
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners

XBIO : 3.20 (unch)

Business Summary

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an...

See More

Key Turning Points

3rd Resistance Point 3.54
2nd Resistance Point 3.40
1st Resistance Point 3.30
Last Price 3.20
1st Support Level 3.07
2nd Support Level 2.93
3rd Support Level 2.83

See More

52-Week High 13.93
Fibonacci 61.8% 9.33
Fibonacci 50% 7.91
Fibonacci 38.2% 6.50
Last Price 3.20
52-Week Low 1.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.